<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211030052912N7</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-08-03</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of histological changes in the biceps brachii muscle after dry needling in stroke patients</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of histological changes in the biceps brachii muscle after dry needling in stroke patients using theechovariation index: a double-blind Randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-08-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>39</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/92123</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Other, Purpose: Health service research, Randomization description: Randomization will be carried out via the website www.sealedenvelope.com.In this method, 5 blocks of 6 will be determined according to three groups. Then, each sequence will be recorded on a card and placed inside an envelope. In the order of patients' arrival, the envelopes will be opened and the assigned group of that participant will be determined. In this double-blind study, patients and the evaluator will be unaware of the type of group assigned. Randomization and evaluation will be carried out by a person who is not involved in the treatment process of the patients and is unaware of the type of intervention, Blinding description: In this double-blind study, patients and the evaluator are unaware of the type of group assigned. Randomization and evaluation will be performed by a person who is not involved in the treatment process of the patients and is unaware of the type of intervention.
For the sham needle, a monofilament head, which is plastic and resembles a shoe, will be used that is only moved slowly over the skin and does not penetrate into the tissue.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Stroke.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: will receive ten sessions of therapeutic exercise with the Bobath approach and five sessions of dry needling of the biceps muscle (every other session). Method of dry needling of the biceps muscle: the patient is placed in a supine position with the upper limb beside the body and the elbow in extension. Five centimeters above the middle of the elbow crease line (distal one-third of the muscle), the needle is inserted perpendicularly into the motor point of the muscle and moved for 1 minute in a fast in/fast out manner in different directions in a conical pattern. Intervention 2: Intervention group2:Will receive only five sessions of dry needling of the biceps muscle with intervals similar to the previous groups. Intervention 3: Control group:Ten sessions of therapeutic exercise with the Bobath approach, along with five sessions of sham needling of the biceps muscle (every other session), will be administered at the same previous points. For the sham needling, a plastic monofilament tip similar to a needle will be used, which is only slowly moved over the skin and does not penetrate the tissue.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After de-identifying people, the consent form and evaluation data can be shared.

When:
One year after the article was published

To whom:
Researchers working in educational, research and academic institutions

Conditions:
For the purpose of conducting research, with obtaining permission, attributing the source, and maintaining data confidentiality.

Where to obtain:
Email, phone number

How to obtain:
One week after sending an email or making a phone call

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Somaye azarnia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr. Heshmat Hospital, 15 Khordad Blvd., Rasht</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4193955588</zip>
        <telephone>+98 13 3366 9066</telephone>
        <email>azarnia.pt.82@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Somaye Azarnia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr. Heshmat Hospital,15 Khordad Blvd.,Rasht</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4193955588</zip>
        <telephone>+98 13 3366 9066</telephone>
        <email>azarnia.pt.82@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1 Hemiplegia due to first ischemic stroke
Age between 40 and 65 years
At least 6 months after stroke
Spasticity severity 1 or higher in elbow flexor muscles
No use of anti-spasticity drugs during the study period
No other nervous system disorders</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having a second stroke
Unwanted to continue cooperation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>163</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Cerebral infarctionIncl.:occlusion and stenosis of cerebral and precerebral arteries (including truncus brachiocephalicus), resulting in cerebral infarction</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: will receive ten sessions of therapeutic exercise with the Bobath approach and five sessions of dry needling of the biceps muscle (every other session). Method of dry needling of the biceps muscle: the patient is placed in a supine position with the upper limb beside the body and the elbow in extension. Five centimeters above the middle of the elbow crease line (distal one-third of the muscle), the needle is inserted perpendicularly into the motor point of the muscle and moved for 1 minute in a fast in/fast out manner in different directions in a conical pattern.</i_keyword>
      <i_keyword>Intervention group2:Will receive only five sessions of dry needling of the biceps muscle with intervals similar to the previous groups.</i_keyword>
      <i_keyword>Control group:Ten sessions of therapeutic exercise with the Bobath approach, along with five sessions of sham needling of the biceps muscle (every other session), will be administered at the same previous points. For the sham needling, a plastic monofilament tip similar to a needle will be used, which is only slowly moved over the skin and does not penetrate the tissue.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>. Timepoint: . Method of measurement: .</prim_outcome>
      <prim_outcome>Echovariance index. Timepoint: Before starting the intervention, after the treatment ends, and one week after the completion of the sessions. Method of measurement: Ultrasound and multifrequency linear transducers with a maximum frequency of 11 MHz will be used.</prim_outcome>
      <prim_outcome>Rang of motion. Timepoint: Before starting the intervention, after the treatment ends, and one week after the completion of the sessions. Method of measurement: By standard goniometer model COMED.</prim_outcome>
      <prim_outcome>Functional assessment. Timepoint: Before starting the intervention, after the treatment ends, and one week after the completion of the sessions. Method of measurement: Upper limb function is evaluated according to the Brunnstrom stages of recovery.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-07-27</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Keshavarz Blvd., Corner of Qods, Headquarters of Tehran University of Medical Sciences, 6th Floor Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
